drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Autologous, gene-modified T lymphocytes expressing a chimeric antigen receptor targeting CD276 (B7-H3) for recurrent/progressive glioblastoma; intracranial (Ommaya) delivery with weekly dosing in a 3+3 escalation (5×10^6 then 1×10^7 cells). Redirects T cells independent of native TCR, activating CAR signaling (CD3ζ with costimulation), cytokine release, and perforin/granzyme-mediated cytotoxicity against CD276-positive tumor and vasculature.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Autologous T lymphocytes engineered to express a CD276 (B7-H3)-specific chimeric antigen receptor. CAR binding to CD276 on tumor cells and tumor vasculature activates CD3ζ and costimulatory signaling, driving T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing independent of the native TCR.
drug_name
WL276 CAR-T cells (WL276001)
nct_id_drug_ref
NCT06691308